Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Photo

Shorla Oncology meet Nancy Pelosi, Madam Speaker of the US House of Representatives

March 7th 2022May 7th 2019

Read More

Banner

DCAT New York City, USA

March 7th 2022March 15th 2019

Read More

Photo

Biotech Showcase at J.P. Morgan Annual Healthcare Conference, San Francisco, USA

March 7th 2022January 4th 2019

Read More

Photo

Shorla Oncology attend Harvard Business School 19th annual Healthcare conference, Boston, USA

March 7th 2022November 20th 2018

Read More

Photo

Shorla Oncology visit North Carolina Research Triangle, USA

March 7th 2022November 5th 2018

Read More

Photo

Shorla Oncology at SelectUSA Investment Summit, Washington, USA

March 7th 2022July 8th 2018

Read More

Banner

Shorla Oncology attending CPhI North America, Philadelphia, USA

March 7th 2022April 18th 2018

Read More

Newer posts
Page1 … Page11 Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.